TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates Accessibility StatementSkip NavigationTheravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS EnrollmentNEW YORK, March 25, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders who lost money are encourage ...

Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File No. 001-36033 THERAVANCE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Cayman Islands 98-1226628 (Sta ...

Core Insights - Theravance Biopharma reported a fourth-quarter 2025 adjusted earnings of 6 cents per share, missing the Zacks Consensus Estimate of 44 cents, compared to an adjusted loss of 5 cents per share in the same quarter last year [2][7] - Total revenues for the quarter were $45.9 million, falling short of the Zacks Consensus Estimate of $60 million, but representing a 145% year-over-year increase, primarily driven by $25 million in licensing and milestone revenues from partner Viatris related to Yupelri sales [3][6] - Year-to-date, Theravance's shares have declined by 25.1%, while the industry has seen a smaller decline of 3.1% [5] Financial Performance - Collaboration revenues amounted to $20.8 million, reflecting an 11.4% year-over-year increase, alongside $25 million in licensing and milestone revenues from Yupelri sales [6][8] - For the full year 2025, Theravance reported total revenues of $107.4 million, a 67% increase year-over-year, with an adjusted loss of 14 cents per share, an improvement from the prior year's loss of 33 cents [10] Pipeline and Strategic Changes - Theravance announced the discontinuation of the ampreloxetine program following a failure to meet primary endpoints in the pivotal phase III CYPRESS study [11][12] - The company is undergoing a major organizational restructuring, aiming to reduce its workforce by approximately 50% and cut operating costs by about 60% relative to 2025's operating cost of $111.1 million, with expected annualized savings of around $70 million by Q3 2026 [13][14] Future Outlook - Theravance anticipates having around $400 million in cash by the first quarter of 2026, along with potential milestone payments from Trelegy and Yupelri [16] - The restructuring and continued sales of Yupelri are projected to drive annualized cash flow of approximately $60-$70 million starting in Q3 2026 [14]

Theravance Biopharma (TBPH) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.T ...

Theravance Biopharma (TBPH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -86.47%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.03 per share when it actually produced earnings of $0.04, delivering a surprise of +233.33%.Over the last four ...

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Accessibility StatementSkip Navigation DUBLIN, March 19, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the fourth quarter and full year of 2025. "We ended 2025 on a positive note from a financial perspective, achieving another record quarter of non-GAAP profitability, hitting a new ...

TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP Accessibility StatementSkip NavigationTheravance Biopharma Reaffirmed Financial Guidance Repeatedly Without Disclosing the Material Risk That Its Pivotal Trial Could FailNEW YORK, March 18, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% when shares collapsed on March 3, 2026. In the quarters leading up to that drop, management reaffirmed financial guidance -- including ...

Core Insights - Theravance Biopharma, Inc. is under investigation for potential violations of federal securities laws following a significant stock drop after the failure of the CYPRESS trial [1][3]. Financial Performance - In Q3 2025, the company projected near-term milestones totaling $75 million for the fourth quarter, with $50 million expected from Trelegy and $25 million from YUPELRI [2]. - The CFO reaffirmed all elements of the 2025 financial guidance during the Q2 2025 earnings call, without addressing potential impacts from the CYPRESS trial failure [2]. Recent Developments - On March 3, 2026, Theravance announced that the CYPRESS trial did not meet its primary endpoint, leading to an accelerated strategic review and the termination of the ampreloxetine program [3]. - Following this announcement, the company's stock experienced a decline of approximately 26% in a single trading session [3].

Core Viewpoint - Theravance Biopharma (TBPH) is experiencing significant selling pressure, with a 33.7% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst consensus for better-than-expected earnings [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - TBPH's current RSI reading is 21.51, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that earnings estimates for TBPH have increased significantly, with a 2533.3% rise in the consensus EPS estimate over the last 30 days, indicating potential price appreciation [7]. - TBPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [8].

Core Viewpoint - Theravance Biopharma (TBPH) is experiencing significant selling pressure, with a 30.6% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better-than-expected earnings [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is overbought or oversold, with readings below 30 typically signaling an oversold condition [2]. - TBPH's current RSI reading of 21.54 suggests that the heavy selling may be exhausting, indicating a possible bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that earnings estimates for TBPH have significantly increased, with a 2533.3% rise in the consensus EPS estimate over the last 30 days, which often correlates with near-term price appreciation [7]. - TBPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further indicating a potential turnaround [8].